ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026)
ImmunityBio's (IBRX) quarterly Income from Continuing Operations came in at 632788000.0 in Q1 2026, down 388.01% year-on-year from 219707512.55 in Q1 2025, and down 921.32% on a QoQ basis from 61958000.0 in Q4 2025.
ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Income from Continuing Operations data on file, last reported at 632788000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 388.01% year-over-year to 632788000.0 in Q1 2026; TTM through Mar 2026 was 854629000.0, a 108.86% decrease from a year earlier, with the FY2025 full-year figure at 351472000.0, up 15.03% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 632788000.0, down from 61958000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IBRX reached as high as 59179000.0 in Q4 2024 and fell as low as 632788000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 141124235.29 across 5 years, with a median of 108326000.0 in 2022.
- Across the five-year window, Income from Continuing Operations jumped 74.65% in 2024 and sank 388.01% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 108326000.0 in 2022, then tumbled by 115.47% to 233414000.0 in 2023, then soared by 74.65% to 59179000.0 in 2024, then slipped by 4.7% to 61958000.0 in 2025, then slumped by 921.32% to 632788000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 632788000.0 in Q1 2026, 61958000.0 in Q4 2025, and 67309000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | ImmunityBio | 7.35 Bn | 6.97 Bn | 43.97 Mn | -632.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -632.79 Mn |
| Dec 31, 2025 | -61.96 Mn |
| Sep 30, 2025 | -67.31 Mn |
| Jun 30, 2025 | -92.57 Mn |
| Mar 31, 2025 | -129.67 Mn |
| Dec 31, 2024 | -59.18 Mn |
| Sep 30, 2024 | -85.75 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.41 Mn |
| Sep 30, 2023 | -95.64 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -108.33 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -88.43 Mn |
| Jun 30, 2021 | -89.39 Mn |